<DOC>
	<DOCNO>NCT01364389</DOCNO>
	<brief_summary>The study two-week , single-blinded , double-dummy , randomize , active-controlled , parallel group design , follow-up period total study duration 6-month , non-randomized , open-label phase monitor safety , tolerability , responder , flare . It multicentric , multinational study . The protocol seek enroll total 30 patient , randomize 3 arm ratio 1:1:1 . Patients maximum screening period 7 day randomization D1 dose period 15 day follow follow up-period 154 day , 4 month ( 112 day ) last biologic dose , whichever great , follow unblinded re-dosing case disease flare .</brief_summary>
	<brief_title>A 3-arm Proof Concept Study AIN457 , ACZ885 Corticosteroids Patients With Polymyalgia Rheumatica</brief_title>
	<detailed_description />
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Patients must meet following feature : Patients ≥ 50 ≤ 85 year CRP &gt; 1.0 mg/dl OR ESR &gt; 30 mm/hr New bilateral shoulder and/or hip pain Early morning stiffness ≥ 60 min Duration illness &gt; 1 week A negative 5 U PPD skin test ( ≤ 5 mm induration ) screen Active infection current use antibiotic Known HIV , HCV HBV Previous therapy methotrexate immunosuppressive agent within three month prior baseline History malignancy successfully treat nonmetastatic cutaneous squamous cell basal cell carcinoma and/or localize carcinoma situ cervix within five year prior study entry Presence rheumatoid arthritis inflammatory arthritic process ( feature GCA ( Giant Cell Artertitis ) , spondyloarthropathies ) , connective tissue disease , druginduced myopathy , endocrine disorder , neurological disorder , chronic pain syndrome , assess base line screen include TSH , CK , RF , CCP , ANA , serum protein electrophoresis , urinalysis . Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Polymyalgia Rheumatica</keyword>
	<keyword>Inflammatory Disease</keyword>
	<keyword>Rheumatic Disease</keyword>
</DOC>